DKSH, the leading Market Expansion Services provider with a focus on Asia, has extended its partnership with Alexion Pharmaceuticals to market and distribute rare disease medicine SOLIRIS® (eculizumab).
Media release
Hong Kong, June 11, 2020 – DKSH Business Unit Healthcare, Asia's leading partner for healthcare companies seeking to grow their business in Asia, has extended its partnership with Alexion Pharmaceuticals. The business partner is a global biopharmaceutical company focused serving patients and families with rare and devastating disorders. DKSH will oversee the local operations of its rare disease medicine SOLIRIS (eculizumab) in Hong Kong, Macau and Taiwan.
Alexion's medicine SOLIRIS treats the rare diseases paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Both are serious life-threatening diseases that affect children and adults. DKSH will manage a variety of commercial and non-commercial activities as well as warehousing and distribution of SOLIRIS in Hong Kong, Macau and Taiwan. DKSH's full agency model will ensure coverage of key hospitals and healthcare practitioners treating rare disease patients, provision of medical information to healthcare professionals, delivery of patient solutions programs, regulatory support and pharmacovigilance monitoring – all in adherence and compliance to local regulations.
“We are proud to extend our partnership with Alexion, a company which, like us, is committed to improving the health of people impacted by devastating diseases,” said Bijay Singh, Global Head of Business Unit Healthcare, DKSH. “With our broad range of capabilities and our deep understanding of the healthcare market in each country, DKSH is well positioned to support physicians to continue to help people living with aHUS and PNH, for which unfortunately there is no cure.”
For further information, please contact:
DKSH Business Unit Healthcare
Sheena Flannery
Director, Group Communications
+66 2 220 9739
sheena.flannery@dksh.com